Altered Expression of the Epithelial Mucin MUC1 Accompanies Endoscopic Recurrence of Postoperative Crohn’s Disease
- 1 February 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 55 (2) , 127-133
Abstract
Background: MUC1-glycoprotein is expressed at low levels and in fully glycosylated form on epithelial cells. Inflammation causes MUC1 overexpression and hypoglycosylation. We hypothesized that overexpression of hypoglycosylated MUC1 would be found in postoperative Crohn’s disease (CD) recurrence and could be considered an additional biomarker of recurrence severity. Methods: We examined archived neo-terminal ileum biopsies from patients with prior ileocecal resection who had postoperative endoscopic assessment of CD recurrence and given a Rutgeerts ileal recurrence score. Consecutive tissue sections were stained using 2 different anti-MUC1 antibodies, HMPV that recognizes all forms of MUC1 and 4H5 that recognizes only inflammation-associated hypoglycosylated MUC1. Results: A total of 71 postoperative CD patients were evaluated. There was significant increase in MUC1 expression of both glycosylated/normal (PP<0.0001) forms in patients with severe endoscopic CD recurrence (i3+i4), ileal score i2, compared with patients in endoscopic remission (i0+i1). Results were similar regardless of anti-TNF-α use. Although MUC1 expression and Rutgeerts scores were in agreement when characterizing the majority of cases, there were a few exceptions where MUC1 expression was characteristic of more severe recurrence than implied by Rutgeerts score. Conclusions: MUC1 is overexpressed and hypoglycosylated in neo-terminal ileum tissue of patients with postoperative CD recurrence. Increased levels are associated with more severe endoscopic recurrence scores, and this is not influenced by anti-TNF-α use. Discrepancies found between Rutgeerts scores and MUC1 expression suggest that addition of MUC1 as a biomarker of severity of postoperative CD recurrence may improve categorization of recurrence status and consequently treatment decisions.Keywords
This publication has 24 references indexed in Scilit:
- Prevention of colitis-associated colon cancer using a vaccine to target abnormal expression of the MUC1 tumor antigenOncoImmunology, 2012
- MUC1 Protein Expression in Tumor Cells Regulates Transcription of Proinflammatory Cytokines by Forming a Complex with Nuclear Factor-κB p65 and Binding to Cytokine PromotersJournal of Biological Chemistry, 2011
- Cytokine and Progesterone Receptor Interplay in the Regulation of MUC1 Gene ExpressionMolecular Endocrinology, 2010
- Inflammation Driven by Overexpression of the Hypoglycosylated Abnormal Mucin 1 (MUC1) Links Inflammatory Bowel Disease and PancreatitisPancreas, 2010
- Vaccine against MUC1 Antigen Expressed in Inflammatory Bowel Disease and Cancer Lessens Colonic Inflammation and Prevents Progression to Colitis-Associated Colon CancerCancer Prevention Research, 2010
- Aberrant Expression of MUC1 Mucin in Pediatric Inflammatory Bowel DiseasePediatric and Developmental Pathology, 2010
- Postoperative endoscopic surveillance in Crohn's disease: bottom up or top down?Gastrointestinal Endoscopy, 2007
- Pro-inflammatory Cytokines Up-regulate MUC1 Gene Expression in Oral Epithelial CellsJournal of Dental Research, 2003
- Synergistic stimulation of MUC1 expression in normal breast epithelia and breast cancer cells by interferon‐γ and tumor necrosis factor‐αJournal of Cellular Biochemistry, 2002
- Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms.Gut, 1992